RhumbLine Advisers
RUBY

RhumbLine Advisers’s Rubius Therapeutics, Inc RUBY Stock Holding History

RhumbLine Advisers’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-46,907
Closed -$258K – 3310
2022
Q1 		$258K Sell
46,907
-1,114
-2% -$7.08K ﹤0.01% 2684
2021
Q4 		$465K Sell
48,021
-10,662
-18% -$148K ﹤0.01% 2540
2021
Q3 		$1.05M Buy
58,683
+1,652
+3% +$35.9K ﹤0.01% 2211
2021
Q2 		$1.39M Sell
57,031
-9,810
-15% -$245K ﹤0.01% 2104
2021
Q1 		$1.77M Buy
66,841
+7,585
+13% +$111K ﹤0.01% 1969
2020
Q4 		$450K Buy
59,256
+8,273
+16% +$49.1K ﹤0.01% 2483
2020
Q3 		$255K Sell
50,983
-7,365
-13% -$39K ﹤0.01% 2588
2020
Q2 		$349K Buy
58,348
+12,893
+28% +$76.1K ﹤0.01% 2503
2020
Q1 		$202K Buy
45,455
+93
+0.2% +$691 ﹤0.01% 2581
2019
Q4 		$431K Buy
45,362
+304
+0.7% +$2.94K ﹤0.01% 2426
2019
Q3 		$354K Sell
45,058
-215
-0.5% -$2.5K ﹤0.01% 2490
2019
Q2 		$712K Buy
45,273
+3,208
+8% +$51.8K ﹤0.01% 2216
2019
Q1 		$761K Buy
42,065
+25,736
+158% +$395K ﹤0.01% 2150
2018
Q4 		$263K Buy
16,329
+7,711
+89% +$141K ﹤0.01% 2603
2018
Q3 		$207K Buy
+8,618
New +$197K ﹤0.01% 2714

Other funds holding RUBY

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AFM
Abbot Financial Management Andover, Massachusetts $239M AUM 27.19% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

RhumbLine Advisers's RUBY Position: Q2 2022 in Review

RhumbLine Advisers sold out of Rubius Therapeutics, Inc (RUBY) in Q2 2022, closing a stake of 46,907 shares — an estimated $258K sold.

RhumbLine Advisers first reported a position in RUBY in Q3 2018 and held it in 15 quarters. The position peaked at $1.77M in Q1 2021. 72 funds tracked by Wall St. Rank hold RUBY as of Q2 2022.

  • RhumbLine Advisers reported no remaining Rubius Therapeutics, Inc position as of Q2 2022 after selling out during the quarter.
  • RhumbLine Advisers sold 46,907 Rubius Therapeutics, Inc shares in Q2 2022, an estimated $258K.
  • RhumbLine Advisers first reported a position in Rubius Therapeutics, Inc in Q3 2018 and held it in 15 quarters.
  • RhumbLine Advisers's Rubius Therapeutics, Inc position peaked at $1.77M in Q1 2021.
  • 72 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q2 2022.

Based on RhumbLine Advisers's 13F filing for Q2 2022, filed 11 Aug 2022.